Abstract: Background: Due to their mechanism of action, sodium-glucose cotransporter-2 inhibitors (SGLT2is) carry a presumed increased risk of urinary tract infection (UTI) which …
Abstract: Background: The effect of sodium-glucose co-transporter-2 inhibitors (SGLT2i) on cardiovascular disease and CKD may be limited if discontinued in persons with CKD. We …
Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the progression of chronic kidney disease (CKD) to end-stage renal disease, doubling of creatinine, and death …
Abstract: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk for several adverse outcomes among patients with diabetic kidney disease. Yet, optimal timing for …